198 related articles for article (PubMed ID: 11782386)
1. Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization.
Shridhar V; Sen A; Chien J; Staub J; Avula R; Kovats S; Lee J; Lillie J; Smith DI
Cancer Res; 2002 Jan; 62(1):262-70. PubMed ID: 11782386
[TBL] [Abstract][Full Text] [Related]
2. Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer.
Fullwood P; Marchini S; Rader JS; Martinez A; Macartney D; Broggini M; Morelli C; Barbanti-Brodano G; Maher ER; Latif F
Cancer Res; 1999 Sep; 59(18):4662-7. PubMed ID: 10493522
[TBL] [Abstract][Full Text] [Related]
3. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
4. Genetic analysis of early- versus late-stage ovarian tumors.
Shridhar V; Lee J; Pandita A; Iturria S; Avula R; Staub J; Morrissey M; Calhoun E; Sen A; Kalli K; Keeney G; Roche P; Cliby W; Lu K; Schmandt R; Mills GB; Bast RC; James CD; Couch FJ; Hartmann LC; Lillie J; Smith DI
Cancer Res; 2001 Aug; 61(15):5895-904. PubMed ID: 11479231
[TBL] [Abstract][Full Text] [Related]
5. Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma.
Liu FS; Dong JT; Chen JT; Hsieh YT; Ho ES; Hung MJ
Gynecol Oncol; 2000 Jul; 78(1):10-5. PubMed ID: 10873402
[TBL] [Abstract][Full Text] [Related]
6. Mapping of chromosome 3p deletions in human epithelial ovarian tumors.
Lounis H; Mes-Masson AM; Dion F; Bradley WE; Seymour RJ; Provencher D; Tonin PN
Oncogene; 1998 Nov; 17(18):2359-65. PubMed ID: 9811467
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
[TBL] [Abstract][Full Text] [Related]
8. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.
Cvetkovic D; Pisarcik D; Lee C; Hamilton TC; Abdollahi A
Gynecol Oncol; 2004 Dec; 95(3):449-55. PubMed ID: 15581945
[TBL] [Abstract][Full Text] [Related]
9. Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis.
Gorringe KL; Ramakrishna M; Williams LH; Sridhar A; Boyle SE; Bearfoot JL; Li J; Anglesio MS; Campbell IG
Genes Chromosomes Cancer; 2009 Oct; 48(10):931-42. PubMed ID: 19603523
[TBL] [Abstract][Full Text] [Related]
10. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
Lu KH; Patterson AP; Wang L; Marquez RT; Atkinson EN; Baggerly KA; Ramoth LR; Rosen DG; Liu J; Hellstrom I; Smith D; Hartmann L; Fishman D; Berchuck A; Schmandt R; Whitaker R; Gershenson DM; Mills GB; Bast RC
Clin Cancer Res; 2004 May; 10(10):3291-300. PubMed ID: 15161682
[TBL] [Abstract][Full Text] [Related]
11. Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer.
Kikuchi R; Tsuda H; Kozaki K; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2008 Jul; 68(13):5067-75. PubMed ID: 18593905
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
L'Espérance S; Popa I; Bachvarova M; Plante M; Patten N; Wu L; Têtu B; Bachvarov D
Int J Oncol; 2006 Jul; 29(1):5-24. PubMed ID: 16773180
[TBL] [Abstract][Full Text] [Related]
13. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
[TBL] [Abstract][Full Text] [Related]
14. Marked allelic imbalance on chromosome 5q31 does not explain alpha-catenin expression in epithelial ovarian cancer.
Tuhkanen H; Anttila M; Kosma VM; Puolakka J; Juhola M; Heinonen S; Mannermaa A
Gynecol Oncol; 2004 Aug; 94(2):416-21. PubMed ID: 15297182
[TBL] [Abstract][Full Text] [Related]
15. Differential gene expression between normal and tumor-derived ovarian epithelial cells.
Ismail RS; Baldwin RL; Fang J; Browning D; Karlan BY; Gasson JC; Chang DD
Cancer Res; 2000 Dec; 60(23):6744-9. PubMed ID: 11118061
[TBL] [Abstract][Full Text] [Related]
16. Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression.
Stronach EA; Sellar GC; Blenkiron C; Rabiasz GJ; Taylor KJ; Miller EP; Massie CE; Al-Nafussi A; Smyth JF; Porteous DJ; Gabra H
Cancer Res; 2003 Dec; 63(24):8648-55. PubMed ID: 14695176
[TBL] [Abstract][Full Text] [Related]
17. Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival.
Pils D; Horak P; Gleiss A; Sax C; Fabjani G; Moebus VJ; Zielinski C; Reinthaller A; Zeillinger R; Krainer M
Cancer; 2005 Dec; 104(11):2417-29. PubMed ID: 16270321
[TBL] [Abstract][Full Text] [Related]
18. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.
Rosen DG; Wang L; Jain AN; Lu KH; Luo RZ; Yu Y; Liu J; Bast RC
Clin Cancer Res; 2004 Oct; 10(19):6559-66. PubMed ID: 15475444
[TBL] [Abstract][Full Text] [Related]
19. Physical and transcript map of the region between D6S264 and D6S149 on chromosome 6q27, the minimal region of allele loss in sporadic epithelial ovarian cancer.
Liu Y; Emilion G; Mungall AJ; Dunham I; Beck S; Le Meuth-Metzinger VG; Shelling AN; Charnock FM; Ganesan TS
Oncogene; 2002 Jan; 21(3):387-99. PubMed ID: 11821951
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional profiling reveals that several common fragile-site genes are downregulated in ovarian cancer.
Denison SR; Becker NA; Ferber MJ; Phillips LA; Kalli KR; Lee J; Lillie J; Smith DI; Shridhar V
Genes Chromosomes Cancer; 2002 Aug; 34(4):406-15. PubMed ID: 12112530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
